Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124612 | 0.84 | TSHR (0.62) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3131935 | 0.82 | TSHR (0.63) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL31347917 | 0.81 | TSHR (0.57) | TSHRALDH1A1LMNAHTTPOLB | |
| SCHEMBL5826839 | 0.80 | TSHR (0.60) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6691847 | 0.80 | LMNA (0.44) | TSHRALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL4551788 | 0.79 | POLB (0.60) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5875799 | 0.79 | TSHR (0.59) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6196657 | 0.78 | POLB (0.61) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5875796 | 0.78 | MEN1 (0.60) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6993844 | 0.77 | POLB (0.61) | TSHRKDM4EALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001022918-A2 | METHOD OF PREPARATION OF SILDENAFIL | INST FARMACEUTYCZNY (PL) | 2001-04-05 | — | — | WO | claimed |
| EP-2024369-A2 | NOVEL PROCESS FOR THE PREPARATION OF SILDENAFIL CITRATE | Matrix Laboratories Ltd (IN) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007141805-A2 | NOVEL PROCESS FOR THE PREPARATION OF SILDENAFIL CITRATE | MATRIX LABORATORIES LIMITED (IN) | 2007-12-13 | — | — | WO | disclosed |
| US-7067660-B2 | such as 1-(4-ethoxy-3-formylphenylsulfonyl)-4-methylpiperazine; for use as anti-impotence agent | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1296983-B1 | NOVEL PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LTD (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040110948-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| US-6730786-B2 | REACTING A BENZAMIDINE COMPOUND WITH A AMIDE SUBSTITUTED PYRAZOLE COMPOUND | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| EP-1296983-A1 | NOVEL PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001098303-A1 | NOVEL PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001022918-A2 | METHOD OF PREPARATION OF SILDENAFIL | INST FARMACEUTYCZNY (PL) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001022918-A2 | METHOD OF PREPARATION OF SILDENAFIL | INST FARMACEUTYCZNY (PL) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | SDHA, NDUFS3, NDUFS2 | TSHR 2524/4885KDM4E 3008/4885ALDH1A1 163/4885 |
| US-20040110948-A1 | Novel process for the preparation of pyrazolopyrimidinones | SDHA, NDUFS3, NDUFS2 | TSHR 2524/4885KDM4E 3008/4885ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.